Next-generation DNA and RNA sequencing requires intact nucleic acids from high-quality human tissue samples to better elucidate the molecular basis of cancer. We have developed a prostate biobanking protocol to acquire suitable samples for sequencing without compromising the accuracy of clinical diagnosis. To assess the clinical implications of implementing this protocol, we evaluated 105 consecutive radical prostatectomy specimens from November 2008 to February 2009. Alternating levels of prostate samples were submitted to Surgical Pathology as formalin-fixed, paraffin-embedded blocks and to the institutional biobank as frozen blocks. Differences in reported pathologic characteristics between clinical and procured specimens were compared. Clinical staging and grading were not affected by the biobank protocol. Tumor foci on frozen hematoxylin and eosin slides were identified and high-density tumor foci were scored and processed for DNA and RNA extractions for sequencing. Both DNA and RNA were extracted from 22 cases of 44 with high-density tumor foci. Eighty-two percent (18/22) of the samples passed rigorous quality control steps for DNA and RNA sequencing. To date, DNA extracted from 7 cases has undergone whole-genome sequencing, and RNA from 18 cases has been RNA sequenced. This protocol provides prostate tissue for high-throughput biomedical research and confirms the feasibility of actively integrating prostate cancer into The Cancer Genome Atlas Program, a member of the International Cancer Genome Consortium.
contents (DNA, RNA, and proteins). Historically, tumorderived prostate cancer cells are difficult to maintain in culture, leading to a greater dependence on tissue sample quality and availability for research purposes. However, identifying tumors and obtaining large quantities of highquality specimens at the time of processing, although not compromising patient care, pose a challenge because of the multifocal and heterogenous nature of the disease. To address this need, we have modified a previously published protocol developed as a part of the National Cancer Institute-funded Prostate Specialized Program of Research Excellence program at the University of Michigan. 7 The biobanking standard operating procedures (SOPs) are performed within the framework of the Weill Cornell Medical College (WCMC) Institutional Biobank. 8 We describe SOPs, quality assessment of samples procured, and clinical impact on 105 consecutive patients who underwent radical prostatectomy (RP).
MATERIALS and METHODS

Cohort Description
The clinical cohort consisted of 105 men from WCMC who underwent RP for clinically localized prostate cancer as monotherapy from November 2008 to February 2009. [9] [10] [11] The clinicopathologic demographics of the cohort are presented in Table 1 .
Collection Protocol
Subjects provided informed consent for the collection of biomaterial for molecular studies, along with clinical follow-up data. 11 To make the process amenable for the TCGA program, the informed consent form was adapted to ensure that the participant understood the benefit and risk of the data generated from genomics studies. Table 2 lists elements in the informed consent required for the TCGA program. Figure 1 illustrates the workflow of the biobank SOPs-patient consent, specimen collection, processing, and pathology review.
Processing Protocol
Blood and urine samples were collected from consented patients preoperatively and perioperatively. The blood and urine samples were processed and stored according to the SOPs of a sponsored National Cancer Institute program-Early Detection Research Network 12 [detailed Early Detection Research Network protocols are in the supplementary data (Supplemental Digital Content1,http://links.lww.com/PDM/A30)].
Prostatectomy Specimens
Radical prostatectomy specimens 10 were transported from the operating room to Surgical Pathology within 30 ± 15 minutes to be accessioned. Under pathologist supervision, the prostatectomy specimen was grossed and processed with recorded start and end times by a trained histology technician. The prostate gland was weighed, measured, and inked with green and black ink to identify the right and left margins, respectively. The seminal vesicles and vas deferens were removed at the prostate base. The base and apical margins were resected from the prostate gland and cut into perpendicular sections. 7 The remaining prostate was sectioned into levels at a thickness of 5 ± 1 mm, depending on the size of the individual prostate, along a transverse plane perpendicular to the posterior surface from the apex to the base. Each level was quartered individually, maintaining the orientation (eg, right anterior, etc.). Alternating levels, including the apical/base margins and seminal vesicles, were submitted for clinical diagnosis as formalin-fixed, paraffinembedded (FFPE) blocks. The remaining levels were quartered and placed into separate cryomolds. Fresh tissue in the cryomold was completely embedded in optimal cutting temperature media and covered by a circular disc of cork. The tissue was then frozen in a mixture of dry ice and methanol and placed in a À 801C tumor banking freezer. The processing time to gross, procure, and freeze an RP specimen ranges between 40 and 60 minutes. Figure 2 illustrates the schematic of the fresh tissue procurement process. The FFPE material was processed according to standard protocols of Surgical Pathology. The complimentary frozen blocks were sectioned and stained with hematoxylin and eosin (H&E) immediately after being frozen. Frozen H&E-stained slides were available to the surgical pathologist as an additional diagnostic material upon request. If requested by the surgical pathologist, frozen tissue could be converted into FFPE material for further submission of diagnostic specimens. Once the surgical pathology report was finalized, the biobanked samples were made available for research studies.
Additional Pathology Review
All the frozen H&E slides of 105 consecutive RP specimens were reviewed after clinical diagnosis. Each frozen H&E slide was assessed for the Gleason score, margin status, and stage (presence or absence of extraprostatic extension), independent of the previously reviewed FFPE blocks. Differences in pathologic findings between the clinically reviewed specimens and procured specimens were annotated and reviewed.
For research purposes, each tumor focus was outlined, the percentage of tumor area in the overall tissue area was calculated, and the total number of tumor foci and zone of origin for each tumor focus were recorded. The outlined method entails marking high-density (HD) tumor area with <10% nontumor contamination in blue, lowdensity (LD) tumor area with >10% nontumor contamination in red, benign epithelial glands in green, and stroma in black framings. All tumors were classified as HD or LD cell population for various downstream applications ( Fig. 3 ). High-density tumor foci from frozen tissue were used for DNA and RNA sequencing, whereas LD tumor foci from matching FFPE tissue were utilized for tissue microarray construction and other studies such as fluorescent in situ hybridization and immunohistochemistry. Benign prostate tissues from the RP specimen were processed for somatic copy number variation studies. 13 
DNA-RNA Extraction
For DNA and RNA extractions, HD tumor foci outlined on the H&E slides were matched with the corresponding areas on the frozen tissue blocks. Extracted nucleic acids were quantified with a NanoDrop 8000 Spectophotometer (Thermo Scientific, Wilmington, DE), and the absorbance ratios at 260nm/280 nm and 260nm/230 nm were evaluated for purity 5 [extraction method is in the supplementary data (Supplemental Digital Content1, http://links.lww.com/PDM/A30)].
Quality Assessment of Samples
Gel electrophoresis was performed to assess the integrity of genomic DNA. The quality of the RNA was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) [(details of the full method is in the supplementary data (Supplemental Digital Content1, http://links.lww.com/PDM/A30)].
Biobank Database
All pertinent information for each case, from molecular to pathologic characteristics, has been maintained in a previously described database called Profiler. 14 
RESULTS
Comparison Study
A total of 105 consecutive prostates were histologically evaluated by 2 independent pathologists (R.E., M.A.R.) on frozen H&E slides and compared with the pathology review from FFPE H&E slides. We identified 4 cases with higher focal Gleason score within the frozen H&E slides, although this did not affect the overall Gleason score. One case was identified with equivocal extraprostatic extension, and another 3 cases exhibited equivocal positive margins. The frozen blocks from these cases were recut and, after further review with the original pathologist of record (M.S.), the pT stage was not altered. Finally, the frozen H&E slides were used to confirm the diagnosis of 2 clinical cases in which minute prostate cancer foci were observed on the complimentary FFPE slides.
Quality of the Samples
Ninety percent of the frozen samples contained cancer and 15% of all the reviewed cases had sufficiently large HD tumor areas for nucleic acid extraction. Among the 105 cases, 22 cases were used for DNA and RNA extraction.
After stringent quality control ( Fig. 4 ), 18 samples from the cohort were used for RNA sequencing at WCMC and sent to the Broad Institute as candidates for DNA sequencing. To date, DNA from 7 samples has been sequenced and 2 of these [sample tracking identifier (STID) 3027 and 3043] have been included in a full prostate cancer genome sequencing study conducted in collaboration with the Broad Institute and WCMC (a total of 7 samples were prepared using this protocol and sequenced in this study). Estimated by the ABSOLUTE algorithm that infers tumor purity and average ploidy from the allele-specific copy number levels (Carter S.L. et al, manuscript in preparation), STID 3027 had a tumor purity of 74% and a mean ploidy of 2.12 and STID 3043 had 68% and 1.956, respectively. 4 Despite the strict protocol, the extracted DNA from HD areas (>90% tumor) had more contamination than expected.
The quality of RNA extracted from the HD tumor area was excellent with a mean RNA integrity number (RIN) value of 8.4. Therefore, samples could be preselected on the basis of HD tumor and deemed suitable for RNA sequencing analysis. Table 3 lists all the individual cases that were used for nucleic acid extraction.
To further elucidate differences between HD and LD tumors, we compared clinicopathologic features of the 2 groups as presented in Table 4 . The cases with HD tumor foci were associated with higher Gleason scores (the generalized Fisher exact test, P<0.0001) and higher PSA (the Wilcoxon rank sum test, P = 0.0401). Differences in age, surgical margin status, tumor stage, and subsequent development of biochemical recurrence were not statistically significant between the 2 groups.
These clinicopathologic features could potentially influence the quality of extracted RNA and help characterize and preselect prospective high-quality tumor samples. In Table 5 , we assessed the distribution of RIN values of the 22 cases with extraction according to clinicopathologic characteristics. No correlation was found in the 2 parameters, possibly because of the sample size and selection bias-all the samples were from cases with HD tumor areas and 21/22 samples had RIN >7.
DISCUSSION
The TCGA Program is a multi-institutional effort to accelerate our understanding of the genetics of cancer using innovative genome analysis technology, including deep sequencing (http://cancergenome.nih.gov/). In order to include prostate cancer in the next phase of TCGA, an efficient method of obtaining high-quality prostate cancer tissue is required without compromising clinical care. The first step required modification of our existing informed consent form to include the purpose of genetic studies, storage of deidentified biospecimens and medical information outside WCMC, and public access to genetic analyses. Second, we had to optimize a prostate biobanking protocol to meet TCGA tissue collection requirements. TCGA collects tumor and matched normal sample for control and requires the tumor sample to consist of >70% tumor nuclei and <20% necrotic area. 16 It is time efficient and resource efficient to collect high-quality biospecimens, as tissue samples undergo independent quality control measures at the TCGA program. Our protocol generates sufficient tissue to make clinical diagnoses of prostate cancer without compromising patient care, while providing fresh, high-quality prostate tissue suitable for genomic studies.
The protocol for partial sampling and procurement of prostate tissue was developed to perform expression profiling of prostate cancer samples, 17 but concern was raised FIGURE 4. A, To assess the integrity of the genomic DNA, gel electrophoresis is performed with 50 ng of DNA. Only samples with DNA of high molecular weight were considered, as the large majority were selected as candidates for single-nucleotide polymorphism arrays and whole-genome sequencing assays. B, The quality of RNA is determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) with an Agilent RNA 6000 Nano Kit. RNA integrity number >7 is required to be considered for gene expression studies. RNA and DNA were extracted from 22 of 105 cases in the study cohort. The samples were subjected to strict quality control before next-generation sequencing. N indicates no; Y, yes.
regarding possible detrimental effects on the pathologic diagnostic parameters. We initially reported that partial sampling (50% vs. whole-mount RP specimens) did not alter diagnostic accuracy, leading to the conclusion that entire sampling offered no significant advantages over the partial sampling technique in detecting adverse pathologic features. 7 Grossfeld et al 18 concluded that prostate sampling methods did not predict clinical outcomes of either secondary treatment or PSA recurrence. Desai et al 19 found higher frequency of extraprostatic extension and seminal vesicle invasion in the complete sampling method, but no differences were apparent in terms of survival rates. A recent study by Salem et al 20 found that whole-mount and systematic sampling produced similar pathologic data, except for estimated tumor volume and multiple margins and similar prognosis for biochemical recurrence. Previous studies compared partial sampling to whole mounting of RP specimens, and others proposed different methods for prostate sampling. 7, 14, 18, 19, [21] [22] [23] [24] [25] [26] [27] [28] However, inconsistent results in these studies reinforced a need for a standardized method and protocol. This study presents our standardized partial sampling protocol to rapidly process and store RP specimens for pathologic diagnosis and research utility. After routine histopathologic evaluation of FFPE and frozen H&E slides within the same case by multiple pathologists, no significant differences were found regarding the ability to detect adverse pathologic features. Frozen samples are not accessible to researchers until a final pathologic diagnosis is made, and frozen H&E slides and blocks are always available to be returned to assist the surgical pathologist. As an additional measure, inconsistent findings from frozen slides are reported to the attending pathologist. Our findings confirm that a partial sampling method for biobanking does not affect the final diagnosis, prognostic information, or relevant clinical care. Our protocol also proves its efficiency in acquiring nucleic acid samples with excellent quality suitable for next-generation sequencing; 81.8% of cases with nucleic acid extraction were RNA sequenced and sent to the Broad Institute for DNA sequencing. Thus, the samples collected through this protocol are likely to meet the standards imposed by TCGA.
Access to high-quality prostate tissue provided by our biobanking protocol permits genome-wide discovery using platforms like next-generation sequencing but also provides the raw material for critical validation studies. For instance, individual tumor RNA can be studied for gene expression using standard techniques such as reverse transcriptase polymerase chain reaction. Rearrangements or somatic copy number aberrations can be investigated using fluorescent in situ hybridization assays or quantitative polymerase chain reaction. Discovered mutations can be validated by conventional Sanger sequencing on expanded numbers of samples. Matching paraffin material allows immunohistochemistry studies of genes of interest at the protein level. Overall, the tissue collection procedure outlined here provides the material for comprehensive investigation of alterations in prostate cancer tissue at DNA, RNA, and protein levels.
In addition, molecular studies on urine and blood specimens enable an exhaustive characterization of germline and somatic changes present in the samples. A potential application for blood samples is in detection of circulating prostate tumor cells, whereas urine samples can be used in polymerase chain reaction-based assays to detect fusion transcripts (ie, urine measurement of TMPRSS2-ERG [29] [30] [31] for the early detection of significant prostate cancer), validating the effort in securing these samples within the biobank.
Potential limitations of this protocol are related to nontumor cell contamination and a bias toward larger tumors. Nontumor cell contamination that is more than expected is most likely because of 2 main factors. First, there tends to be an overestimation of tumor nuclei even in dense areas. Second, the histologic section does not represent the whole tissue block. One way to lower the requirements for using all samples would require either a more careful tumor isolation process such as laser capture microdissection or a more focused genomics approach. For instance, if selected molecular mutations were being investigated, an admixture of benign tissues would not be as critical. Using more sensitive assays could allow for deeper sequencing of known mutations.
In conclusion, we describe a prostate cancer protocol that allows for high-throughput biomedical research without compromising clinical care. Genomic, transcriptomic, as well as proteomic data extracted from highquality fresh tissue could serve as a valuable resource for precise diagnosis, prognosis, and future personalized treatment of prostate cancer and also lead to an increased understanding of tumor biology and the molecular events involved in disease progression.
